SG11201407238VA - 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof - Google Patents

5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

Info

Publication number: SG11201407238VA
Authority: SG; Singapore
Prior art keywords: international; lllll; sutton; surrey; inhibitor
Prior art date: 2012-05-15

Application number

SG11201407238VA

Other languages

English (en)

Inventor

Ian Collins

Thomas Peter Matthews

Da Fonseca Mchardy Tatiana Faria

James Osborne

Michael Lainchbury

Michael Ian Walton

Michelle Dawn Garrett

Original Assignee

Cancer Rec Tech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-15

Filing date

2013-05-14

Publication date

2014-12-30

2013-05-14 Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd

2014-12-30 Publication of SG11201407238VA publication Critical patent/SG11201407238VA/en

Links

230000001225 therapeutic effect Effects 0.000 title abstract 3
YBYYWUUUGCNAHQ-UHFFFAOYSA-N 5-[[4-(morpholin-2-ylmethylamino)-5-(trifluoromethyl)pyridin-2-yl]amino]pyrazine-2-carbonitrile Chemical compound C1=C(NCC2OCCNC2)C(C(F)(F)F)=CN=C1NC1=CN=C(C#N)C=N1 YBYYWUUUGCNAHQ-UHFFFAOYSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 5
108091000080 Phosphotransferase Proteins 0.000 abstract 4
102000020233 phosphotransferase Human genes 0.000 abstract 4
239000003795 chemical substances by application Substances 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
230000006870 function Effects 0.000 abstract 3
108010022394 Threonine synthase Proteins 0.000 abstract 2
102000005497 Thymidylate Synthase Human genes 0.000 abstract 2
102000052567 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Human genes 0.000 abstract 1
108700004581 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Proteins 0.000 abstract 1
102000003915 DNA Topoisomerases Human genes 0.000 abstract 1
108090000323 DNA Topoisomerases Proteins 0.000 abstract 1
230000005778 DNA damage Effects 0.000 abstract 1
231100000277 DNA damage Toxicity 0.000 abstract 1
230000005971 DNA damage repair Effects 0.000 abstract 1
239000012623 DNA damaging agent Substances 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
-1 TFM com pounds Chemical class 0.000 abstract 1
102000007537 Type II DNA Topoisomerases Human genes 0.000 abstract 1
108010046308 Type II DNA Topoisomerases Proteins 0.000 abstract 1
230000001668 ameliorated effect Effects 0.000 abstract 1
230000000340 anti-metabolite Effects 0.000 abstract 1
229940100197 antimetabolite Drugs 0.000 abstract 1
239000002256 antimetabolite Substances 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000011278 mitosis Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000008520 organization Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
230000005855 radiation Effects 0.000 abstract 1
102220240796 rs553605556 Human genes 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Oncology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

SG11201407238VA 2012-05-15 2013-05-14 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof SG11201407238VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261647200P	2012-05-15	2012-05-15
PCT/GB2013/051233 WO2013171470A1 (en)	2012-05-15	2013-05-14	5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

Publications (1)

Publication Number	Publication Date
SG11201407238VA true SG11201407238VA (en)	2014-12-30

Family

ID=48468659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201407238VA SG11201407238VA (en)	2012-05-15	2013-05-14	5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

Country Status (20)

Country	Link
US (3)	US9663503B2 (zh)
EP (2)	EP2855448B1 (zh)
JP (2)	JP6027230B2 (zh)
KR (6)	KR102246265B1 (zh)
CN (2)	CN104302635B (zh)
AU (2)	AU2013261605B2 (zh)
BR (1)	BR112014026801B1 (zh)
CA (1)	CA2870837C (zh)
DK (1)	DK2855448T3 (zh)
ES (1)	ES2624307T3 (zh)
HK (2)	HK1203529A1 (zh)
IL (1)	IL235133A (zh)
IN (1)	IN2014DN09221A (zh)
MX (1)	MX358819B (zh)
NZ (1)	NZ702050A (zh)
PL (1)	PL2855448T3 (zh)
RU (1)	RU2659786C2 (zh)
SG (1)	SG11201407238VA (zh)
WO (1)	WO2013171470A1 (zh)
ZA (1)	ZA201408452B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6073910B2 (ja)	2011-11-09	2017-02-01	キャンサー・リサーチ・テクノロジー・リミテッド	５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
NZ702050A (en)	2012-05-15	2016-08-26	Cancer Rec Tech Ltd	5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
LT3418281T (lt)	2012-12-07	2021-01-11	Vertex Pharmaceuticals Inc.	Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
US9663519B2 (en)	2013-03-15	2017-05-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
KR102153886B1 (ko)	2013-12-06	2020-09-09	버텍스 파마슈티칼스 인코포레이티드	Atr 키나제 억제제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물, 이의 제조 방법, 이의 상이한 고체형 및 방사성표지된 유도체
PT3152212T (pt)	2014-06-05	2020-03-13	Vertex Pharma	Derivados radiomarcados de um composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor de atr quinase, preparação do dito composto e diferentes formas sólidas do mesmo
RU2736219C2 (ru) *	2014-06-17	2020-11-12	Вертекс Фармасьютикалз Инкорпорейтед	Способ лечения рака с использованием комбинации ингибиторов снк1 и atr
KR20180054657A (ko)	2015-09-30	2018-05-24	버텍스 파마슈티칼스 인코포레이티드	Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법
WO2018094325A1 (en) *	2016-11-18	2018-05-24	The Trustees Of Columbia University In The City Of New York	Therapeutic modulation of oncogenes by pharmacologic top2 targeting for cancer
SG11201908788YA (en) *	2017-03-31	2019-10-30	Seattle Genetics Inc	Combinations of chk1- and wee1 - inhibitors
KR102645511B1 (ko) *	2017-04-10	2024-03-08	시에라 온코로지 엘엘씨	종양 성장을 저해하는 CHK1(SRA737)/PARPi 조합 방법
WO2018191299A1 (en) *	2017-04-10	2018-10-18	Sierra Oncology, Inc.	Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
WO2018222970A1 (en) *	2017-06-01	2018-12-06	Sierra Oncology, Inc.	Biomarkers and patient selection strategies
CN107266897B (zh) *	2017-08-04	2019-05-14	上海跃贝新材料科技股份有限公司	一种低粘度矿物增强pc/pet合金材料及其制备方法
CN112469391A (zh) *	2018-02-26	2021-03-09	塞拉肿瘤学公司	包括chk1抑制剂的癌症的治疗方法
EP3946419A4 (en) *	2019-03-28	2022-12-28	Sierra Oncology, Inc.	METHODS OF TREATING CANCER WITH CHK1 INHIBITORS
MX2021013905A (es) *	2019-05-14	2022-05-18	Sierra Oncology Inc	Métodos de tratamiento del cáncer mediante el uso de inhibidores de chk1.
CN110872277B (zh) *	2019-11-14	2021-06-04	浙江大学	N-取代芳环-2-氨基嘧啶类化合物及用途
CN110680928B (zh) *	2019-12-06	2020-04-28	深圳前海港影生物科技有限公司	抑制黑色素合成的偶联物及其在药品和化妆品中的应用
CN110684083B (zh) *	2019-12-06	2020-05-15	北京诺赛启研再生医学研究院有限公司	抑制黑色素合成的偶联物ii及其在药品和化妆品中的应用
TW202204348A (zh) *	2020-04-07	2022-02-01	美商西爾拉癌症醫學公司	Ｃｈｋ１抑制劑之合成方法
WO2023021328A1 (en) *	2021-08-17	2023-02-23	Bellus Health Cough Inc.	Preparation of a p2x3 antagonist

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773778A (en)	1972-01-24	1973-11-20	Squibb & Sons Inc	Sulfur derivatives of pyrazolo (3,4-b)pyridines
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
HUP9900330A3 (en)	1995-07-06	2001-08-28	Novartis Ag	Pyrrolopyrimidines and processes for the preparation thereof
ATE369854T1 (de)	2001-10-19	2007-09-15	Ortho Mcneil Pharm Inc	2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
EP1441725A1 (en)	2001-10-26	2004-08-04	Aventis Pharmaceuticals Inc.	Benzimidazoles and analogues and their use as protein kinases inhibitors
MXPA04004019A (es)	2001-10-31	2004-07-08	Bayer Healthcare Ag	Derivados de pirimido?4,5-b?indol.
AU2003234464B2 (en)	2002-05-03	2009-06-04	Exelixis, Inc.	Protein kinase modulators and methods of use
WO2003101444A1 (en)	2002-05-29	2003-12-11	Millennium Pharmaceuticals, Inc.	Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
WO2005011597A2 (en)	2003-07-29	2005-02-10	Irm Llc	Compounds and compositions as protein kinase inhibitors
EP1673343A4 (en)	2003-10-08	2008-09-10	Irm Llc	COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
CA2542076C (en)	2003-10-14	2013-02-26	Arizona Board Of Regents On Behalf Of The University Of Arizona	Substituted tricyclic compounds as protein kinase inhibitors
CA2542329A1 (en)	2003-10-16	2005-04-28	Chiron Corporation	2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
US20050096324A1 (en)	2003-11-05	2005-05-05	Zhi-Fu Tao	Macrocyclic kinase inhibitors
US7163939B2 (en)	2003-11-05	2007-01-16	Abbott Laboratories	Macrocyclic kinase inhibitors
AU2005252160A1 (en)	2004-04-13	2005-12-22	Astellas Pharma Inc.	Polycyclic pyrazines as potassium ion channel modulators
US20070054916A1 (en)	2004-10-01	2007-03-08	Amgen Inc.	Aryl nitrogen-containing bicyclic compounds and methods of use
EP1888588A2 (en)	2005-04-28	2008-02-20	SuperGen, Inc.	Protein kinase inhibitors
CA2611295C (en)	2005-06-28	2014-04-22	Sanofi-Aventis	Isoquinoline derivatives as inhibitors of rho-kinase
PE20070335A1 (es)	2005-08-30	2007-04-21	Novartis Ag	Benzimidazoles sustituidos y metodos para su preparacion
TW200745123A (en)	2005-10-06	2007-12-16	Schering Corp	Pyrazolopyrimidines as protein kinase inhibitors
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
GB0616747D0 (en) *	2006-08-24	2006-10-04	Astrazeneca Ab	Novel compounds
WO2008077554A1 (en)	2006-12-27	2008-07-03	Sanofi-Aventis	Cycloalkylamine substituted isoquinoline derivatives
EP2727909A1 (en)	2007-03-16	2014-05-07	The Scripps Research Institute	Inhibitors of focal adhesion kinase
WO2008117050A1 (en)	2007-03-27	2008-10-02	Astrazeneca Ab	Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US8618121B2 (en)	2007-07-02	2013-12-31	Cancer Research Technology Limited	9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
GB0719644D0 (en)	2007-10-05	2007-11-14	Cancer Rec Tech Ltd	Therapeutic compounds and their use
GB0803018D0 (en) *	2008-02-19	2008-03-26	Cancer Rec Tech Ltd	Therapeutic compounds and their use
JP6073910B2 (ja)	2011-11-09	2017-02-01	キャンサー・リサーチ・テクノロジー・リミテッド	５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
NZ702050A (en)	2012-05-15	2016-08-26	Cancer Rec Tech Ltd	5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

2013
- 2013-05-14 NZ NZ702050A patent/NZ702050A/en unknown
- 2013-05-14 KR KR1020207007411A patent/KR102246265B1/ko active IP Right Grant
- 2013-05-14 US US14/396,338 patent/US9663503B2/en active Active
- 2013-05-14 EP EP13723910.9A patent/EP2855448B1/en active Active
- 2013-05-14 CN CN201380025541.3A patent/CN104302635B/zh active Active
- 2013-05-14 SG SG11201407238VA patent/SG11201407238VA/en unknown
- 2013-05-14 PL PL13723910T patent/PL2855448T3/pl unknown
- 2013-05-14 KR KR1020217012299A patent/KR102341637B1/ko active IP Right Grant
- 2013-05-14 KR KR1020247004407A patent/KR20240023685A/ko active Application Filing
- 2013-05-14 CA CA2870837A patent/CA2870837C/en active Active
- 2013-05-14 KR KR1020147031572A patent/KR102090792B1/ko active IP Right Grant
- 2013-05-14 BR BR112014026801-0A patent/BR112014026801B1/pt active IP Right Grant
- 2013-05-14 MX MX2014012881A patent/MX358819B/es active IP Right Grant
- 2013-05-14 EP EP17152400.2A patent/EP3210980B1/en active Active
- 2013-05-14 JP JP2015512120A patent/JP6027230B2/ja active Active
- 2013-05-14 DK DK13723910.9T patent/DK2855448T3/en active
- 2013-05-14 ES ES13723910.9T patent/ES2624307T3/es active Active
- 2013-05-14 KR KR1020227037439A patent/KR102635954B1/ko active IP Right Grant
- 2013-05-14 WO PCT/GB2013/051233 patent/WO2013171470A1/en active Application Filing
- 2013-05-14 CN CN201610652725.8A patent/CN106279142B/zh active Active
- 2013-05-14 IN IN9221DEN2014 patent/IN2014DN09221A/en unknown
- 2013-05-14 AU AU2013261605A patent/AU2013261605B2/en active Active
- 2013-05-14 RU RU2014147105A patent/RU2659786C2/ru active
- 2013-05-14 KR KR1020217041302A patent/KR20210156333A/ko not_active Application Discontinuation
2014
- 2014-10-19 IL IL235133A patent/IL235133A/en active IP Right Grant
- 2014-11-18 ZA ZA2014/08452A patent/ZA201408452B/en unknown
2015
- 2015-04-28 HK HK15104108.4A patent/HK1203529A1/zh unknown
2016
- 2016-10-13 JP JP2016201383A patent/JP6362652B2/ja active Active
2017
- 2017-05-04 US US15/587,270 patent/US10259806B2/en active Active
- 2017-11-28 AU AU2017268508A patent/AU2017268508C1/en active Active
2018
- 2018-02-27 HK HK18102805.1A patent/HK1243408A1/zh unknown
2020
- 2020-12-17 US US17/124,606 patent/US11787792B2/en active Active

Also Published As

Publication number	Publication date
BR112014026801A2 (pt)	2017-06-27
KR102341637B1 (ko)	2021-12-21
JP2015520753A (ja)	2015-07-23
US10259806B2 (en)	2019-04-16
CN106279142A (zh)	2017-01-04
RU2659786C2 (ru)	2018-07-04
AU2013261605B2 (en)	2017-08-31
EP2855448B1 (en)	2017-02-08
CA2870837A1 (en)	2013-11-21
JP6027230B2 (ja)	2016-11-16
CN104302635A (zh)	2015-01-21
RU2014147105A (ru)	2016-07-10
AU2013261605A1 (en)	2014-11-13
EP3210980A1 (en)	2017-08-30
IN2014DN09221A (zh)	2015-07-10
AU2017268508B2 (en)	2019-07-04
CA2870837C (en)	2022-05-10
KR20210047981A (ko)	2021-04-30
US9663503B2 (en)	2017-05-30
ES2624307T3 (es)	2017-07-13
EP3210980B1 (en)	2024-04-03
JP6362652B2 (ja)	2018-07-25
AU2017268508A1 (en)	2017-12-14
MX2014012881A (es)	2015-04-08
NZ702050A (en)	2016-08-26
KR20200038990A (ko)	2020-04-14
ZA201408452B (en)	2016-08-31
US20180022739A1 (en)	2018-01-25
BR112014026801B1 (pt)	2022-03-03
CN104302635B (zh)	2016-07-06
KR20220151007A (ko)	2022-11-11
HK1203529A1 (zh)	2015-10-30
CN106279142B (zh)	2019-05-03
KR102090792B1 (ko)	2020-03-18
MX358819B (es)	2018-09-05
US11787792B2 (en)	2023-10-17
PL2855448T3 (pl)	2017-09-29
WO2013171470A1 (en)	2013-11-21
DK2855448T3 (en)	2017-05-01
KR102635954B1 (ko)	2024-02-13
EP2855448A1 (en)	2015-04-08
HK1243408A1 (zh)	2018-07-13
KR20150023252A (ko)	2015-03-05
AU2017268508C1 (en)	2019-10-17
IL235133A (en)	2017-03-30
JP2017036314A (ja)	2017-02-16
KR20240023685A (ko)	2024-02-22
US20150126471A1 (en)	2015-05-07
KR102246265B1 (ko)	2021-04-29
US20210276990A1 (en)	2021-09-09
KR20210156333A (ko)	2021-12-24

Publication	Publication Date	Title
SG11201407238VA (en)	2014-12-30	5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
SG11201808878UA (en)	2018-11-29	Heterocyclic compounds as ret kinase inhibitors
SG11201408821SA (en)	2015-01-29	Selective pi3k delta inhibitors
SG11201805044WA (en)	2018-07-30	Compounds useful as kinase inhibitors
SG11201803920TA (en)	2018-06-28	Compounds and compositions useful for treating disorders related to ntrk
SG11201810983PA (en)	2019-01-30	Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201805300QA (en)	2018-07-30	Heterocyclic compounds as immunomodulators
SG11201810171SA (en)	2018-12-28	Kras g12c inhibitors
SG11201908820VA (en)	2019-10-30	Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201809714TA (en)	2018-11-29	Piperidines as menin inhibitors
SG11201408750VA (en)	2015-01-29	NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201811470PA (en)	2019-01-30	Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201808907PA (en)	2018-11-29	Inhibitors of activin receptor-like kinase
SG11201900844UA (en)	2019-02-27	Amino pyrimidine ssao inhibitors
SG11201807301SA (en)	2018-09-27	Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201907032RA (en)	2019-08-27	Amino pyrimidine compounds useful as ssao inhibitors
CA2859619C (en)	2022-01-04	Bromodomain inhibitors
SG11201809342YA (en)	2018-11-29	Pyrimidine compounds as jak kinase inhibitors
SG11201408237YA (en)	2015-01-29	Compound as wnt signaling inhibitor, composition, and use thereof
SG11201407793TA (en)	2014-12-30	Compounds and compositions for modulating egfr activity
SG11201408271VA (en)	2015-01-29	Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
SG11201804223TA (en)	2018-06-28	OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
SG11201407372UA (en)	2014-12-30	Nampt inhibitors
SG11201804712PA (en)	2018-07-30	Biofuel
SG11201402986RA (en)	2014-12-30	Kinase inhibitors